Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.

A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

The drugs identified for negotiation in the second round include: Ozempic, Wegovy and other GPL-inhibitors are in high demand in the U.S. Due to that demand, Medicare covering them for diabetes ...

However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey wrench into Novo Nordisk's momentum. The agency announced last week that Ozempic and Wegovy, along with Novo ...

Insurers also ask the Trump administration, which is engaged in a sweeping campaign to eradicate anything related to ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.

If Robert F. Kennedy Jr. and the Trump administration want to make America healthy again, they should let Medicare cover ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their employers.